Highlights in asthma 2005

Cp Violation Highlights: circa 2005

Recent highlights in CP violation phenomena are reviewed. B-factory results imply that CP-violation phase in the CKM matrix is the dominant contributor to the observed CP violation in K and B-physics. Deviations from the predictions of the CKM-paradigm due to beyond the Standard Model CP-odd phase are likely to be a small perturbation. Therefore, large data sample of clean B’s will be needed. P...

Asthma in Alergológica-2005.

BACKGROUND This study analyses the prevalence and the clinical and therapeutic data on asthma collected in consultations as part of Alergológica-2005. MATERIAL AND METHODS A cross-sectional, descriptive, observational, epidemiologic study was carried out. RESULTS The prevalence of asthma was 28%, lower than the 35% prevalence observed in the Alergológica-2002 study. The average age of the p...

The Mectizan® Donation Program – highlights from 2005

Through the Mectizan Donation Program, Merck & Co., Inc. has donated Mectizan (ivermectin, MSD) for the treatment of onchocerciasis worldwide since 1987. Mectizan has also been donated for the elimination of lymphatic filariasis (LF) since 1998 in African countries and in Yemen where onchocerciasis and LF are co-endemic; for LF elimination programs, Mectizan is co-administered with albendazole,...

Lung Cancer Highlights from ASCO 2005.

Exciting news regarding lung cancer was presented at the American Society of Clinical Oncology (ASCO) 2005 Annual Meeting held in Orlando, FL. Last but not least among the big killers, after breast cancer and colorectal cancer, non-small cell lung cancer (NSCLC) can now benefit from the addition of a molecularly targeted agent to standard first-line chemotherapy. The Eastern Cooperative Oncolog...

Controlling asthma. Highlights of the 1999 Canadian Asthma Consensus Report.